^
    3years
    [VIRTUAL] AGX323 - A SAM-competitive, orally available inhibitor of protein arginine methyltransferase 5 (PRMT5) with potent cellular antiproliferative and in vivo antitumor activity against selected solid cancer types (AACR 2021)
    AGX323 demonstrated potentially best-in-class activity in PRMT5 dependent human solid cancer models and exhibited excellent drug-like properties. IND enabling studies are currently planned.
    Preclinical
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    PRMT5 overexpression
    |
    AGX323